PainChek Faces Shareholder Approval Hurdles After $5.5 Million Convertible Note Raise

Convertible Note Raises A$5.5 Million for US Expansion

PainChek Ltd (ASX:PCK) has secured A$5.5 million through the issuance of unsecured convertible notes to a select group of existing sophisticated investors. The fresh capital injection is earmarked to accelerate the company’s North American sales push and bolster its working capital position. The notes carry a 12-month term with a fixed conversion price of $0.195 per share and pay 12% interest monthly in cash.

This funding round arrives at a critical juncture for PainChek, following its landmark agreement with Sabra Health Care REIT, which covers deployment across 350 US aged care homes. CEO Philip Daffas highlighted the financing as a timely boost to support the company’s growth initiatives and commercial strategy in the US market, which also benefits from access to Remote Therapeutic Monitoring (RTM) reimbursement; a significant new revenue stream for the company. The Sabra deal itself is a major step in PainChek’s US rollout, reflecting a broader trend of healthcare REITs adopting AI-driven pain assessment technology 350 US aged care homes.

Terms and Conditions of the Convertible Notes

The convertible notes are issued at face values of A$50,000 each, with a minimum subscription of A$100,000 per investor. Interest accrues at 12% per annum, payable monthly, with an additional 2% penalty interest for any unpaid amounts after redemption. Investors can convert their notes into ordinary shares at any time before maturity at the fixed price, subject to shareholder approval for the issuance of free attaching options.

These options, if approved, will be granted at a ratio of one option for every two shares issued upon conversion, with an exercise price of $0.30 and a 12-month expiry. Should shareholders reject the option issuance and the share price exceeds $0.30, PainChek will compensate noteholders in cash for the difference. The maximum number of shares issuable on conversion is capped at 28.2 million, within the company’s 15% placement capacity under ASX Listing Rule 7.1.

Strategic Use of Funds and Operational Restrictions

The capital raised will primarily fund the expansion of sales and marketing activities in the US, alongside shoring up general working capital. PainChek has also agreed to restrictions on incurring additional debt, paying dividends, or materially altering its business without noteholder consent, ensuring the funds are focused on growth and operational stability.

This convertible note financing follows a series of strategic regulatory and commercial milestones, including the company’s recent FDA clearance and unlocking of RTM reimbursement eligibility, which opens a US market projected to reach US$3 billion annually by 2030. These developments underpin PainChek’s confidence in its growth trajectory despite recent losses reported in earlier periods FDA clearance and US market, RTM reimbursement market.

While the convertible notes provide a crucial capital buffer, the actual impact on PainChek’s sales and share price will depend on the successful execution of its US commercial strategy and shareholder approval for the option issuance. The next shareholder meeting will be pivotal in determining the final structure of this financing and its potential dilution effects.